지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2017.1
- 수록면
- 487 - 494 (8page)
이용수
초록· 키워드
오류제보하기
Background/Aims: In Taiwan, due to budget limitations, the National Health Insurance only allows for a limited period of biologics use in treating moderate to severe Crohn’s disease (CD). We aimed to access the outcomes of CD patients following a limited period use of biologics, specifically focusing on the relapse rate and remission duration; also the response rate to second use when applicable. Methods: This was a multicenter, retrospective, observational study and we enrolled CD patients who had been treated with adalimumab (ADA) according to the insurance guidelines from 2009 to 2015. Results: A total of 54 CD patients, with follow-up of more than 6 months after the withdrawal of ADA, were enrolled. The average period of treatment with ADA was 16.7±9.7 months. After discontinuing ADA, 59.3% patients suffered a clinical relapse. In the univariate analysis, the reason for withdrawal was a risk factor for relapse (P=0.042). In the multivariate analysis, current smoker became an important risk factor for relapse (OR, 3.9; 95% CI, 1.2−14.8; P=0.044) and male sex was another risk factor (OR, 2.9; 95% CI, 1.1−8.6; P=0.049). For those 48 patients who received a second round of biologics, the clinical response was seen in 60.4%, and 1 anaphylaxis occurred. Conclusions: Fifty-nine percent of patients experienced a relapse after discontinuing the limited period of ADA treatment, and most of them occurred within 1 year following cessation. Male sex and current smoker were risk factors for relapse. Though 60.4% of the relapse patients responded to ADA again.
목차
등록된 정보가 없습니다.
참고문헌 (28)
참고문헌 신청
D’Haens GR / 2011 / The London position statement of the World Congress of Gastroenterology on biological therapy for IBD with the European Crohn’s and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? / Am J Gastroenterol 106:199~212
Ben-Horin S / 2015 / Optimizing biologic treatment in IBD: objective measures, but when, how and how often? / BMC Gastroenterol 15:178
Pittet V / 2013 / When do we dare to stop biological or immunomodulatory therapy for Crohn’s disease? Results of a multidisciplinary European expert panel / J Crohns Colitis 7:820~826
The application form of adalimumab for Crohn’s disease in national health insurance
Sands BE. / 2004 / From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation / Gastroenterology 126:1518~1532
Ben-Horin S / 2015 / Optimizing biologic treatment in IBD: objective measures, but when, how and how often? / BMC Gastroenterol 15:178
Pittet V / 2013 / When do we dare to stop biological or immunomodulatory therapy for Crohn’s disease? Results of a multidisciplinary European expert panel / J Crohns Colitis 7:820~826
The application form of adalimumab for Crohn’s disease in national health insurance
Sands BE. / 2004 / From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation / Gastroenterology 126:1518~1532
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Long-term Outcomes after the Discontinuation of Anti-Tumor Necrosis Factor-α Therapy in Patients with Inflammatory Bowel Disease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study
Gut and Liver
2021 .09
-
Comparison of Long-term Outcomes of Infliximab versus Adalimumab in 1,488 Biologic-Naive Korean Patients with Crohn’s Disease
Gut and Liver
2021 .01
-
An Elevated Platelet Count Increases the Risk of Relapse in Ulcerative Colitis Patients with Mucosal Healing
Gut and Liver
2018 .01
-
Effectiveness of transabdominal ultrasonography in predicting clinical relapse of Crohn’s disease
Intestinal research
2024 .01
-
Present and Future after 2016 ADA Guideline
대한외과학회 학술대회 초록집
2018 .11
-
Predictors of Relapse in Patients with Organizing Pneumonia
Tuberculosis and Respiratory Diseases
2015 .01
-
Development of a Novel Endoscopic Scoring System to Predict Relapse after Surgery in Intestinal Behçet’s Disease
Gut and Liver
2018 .01
-
Outcomes of Anti-CD19 CAR-T Treatment of Pediatric B-ALL with Bone Marrow and Extramedullary Relapse
Cancer Research and Treatment
2022 .07
-
Treatment Outcomes in Children and Adolescents with Relapsed or Progressed Solid Tumors: a 20-year, Single-Center Study
Journal of Korean Medical Science
2018 .01
-
Korean clinical practice guidelines on biologics for moderate to severe Crohn’s disease
Intestinal research
2023 .01
-
De-escalation of Therapy in Patients with Quiescent Inflammatory Bowel Disease
Gut and Liver
2023 .03
-
The Value of the Illness-Death Model for Predicting Outcomes in Patients with Non‒Small Cell Lung Cancer
Cancer Research and Treatment
2022 .10
-
Factors Contributing to the Preference of Korean Patients with Crohn’s Disease When Selecting an Anti-Tumor Necrosis Factor Agent (CHOICE Study)
Gut and Liver
2016 .01
-
Comparison of Real-World Outcomes of Infliximab versus Adalimumab in Biologic-Naïve Korean Patients with Ulcerative Colitis: A Population-Based Study
Yonsei Medical Journal
2020 .01
-
Efficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled Trials
Gut and Liver
2016 .01
-
Management of Crohn’s disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease
Intestinal research
2017 .01
-
Aberrant CD3 Expression in a Relapsed Plasma Cell Neoplasm
Journal of Pathology and Translational Medicine
2018 .01
-
Treatment and clinical outcomes of patients relapsing after allogeneic hematopoietic cell transplantation for myelodysplastic syndrome
Blood Research
2018 .01
-
Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study
Intestinal research
2022 .07
이 논문의 저자 정보
최근 본 자료
댓글(0)
0